Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast

Leggi l'articolo originale

The use of immune checkpoint inhibitors (ICIs) has hugely incremented as it has become the standard therapy for a wide range of cancer types. Such monoclonal antibodies act against inhibitory immune receptors cytotoxic T-lymphocyte antigen 4 (CTLA-4) (ipilimumab and tremelimumab) and programmed cell death 1 (PD-1) (nivolumab and pembrolizumab) by boosting the immune response of T cells [1]. Despite favourable oncological outcomes, these treatments have also been associated with a unique spectrum of side-effects known as immune-related adverse events (irAEs) [2].

Lascia un commento